Response to letter by Tsikas et al. 15-deoxy-Δ12,14-PGJ2: An interesting but unapproachable pharmacological target?

Tsikas, Dimitrios; Niemann, Jonas; Beckmann, Bibiana

doi:10.1016/j.ijcard.2014.08.145

Cited by 3 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NAC is an inhibitor (IC 50 , 10-20 μM) of recombinant COX-1-and COX-2-catalyzed formation of PGE 2 [16]. Yet, in the present studies we have no evidence that NAC inhibited COX-dependent formation of PGE 2 and 15(S)-8-iso-PGF 2α which can also be formed by COX [17].…”

Section: Contents Lists Available At Sciencedirectcontrasting

confidence: 75%

N-Acetylcysteine (NAC) inhibits renal nitrite and nitrate reabsorption in healthy subjects and in patients undergoing cardiac surgery: Risk of nitric oxide (NO) bioavailability loss by NAC?

Tsikas

Niemann

Flentje

et al. 2014

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Section: Contents Lists Available At Sciencedirectcontrasting

confidence: 75%

N-Acetylcysteine (NAC) inhibits renal nitrite and nitrate reabsorption in healthy subjects and in patients undergoing cardiac surgery: Risk of nitric oxide (NO) bioavailability loss by NAC?

Tsikas

Niemann

Flentje

et al. 2014

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

“…We appreciate the interest of Tsikas et al [1] in our manuscript [2] and the opportunity to clarify theoretical and experimental aspects describing the effects of 15-deoxy-Δ 12,14 -PGJ 2 (15d-PGJ 2 ) on cardiomyocyte function.…”

Section: Dear Editormentioning

confidence: 99%

“…As the authors [1] correctly point out, the use of N-acetyl-L-cysteine (NAC) as reactive oxygen species (ROS) scavenger is questionable due to the formation of thioethers between NAC and 15d-PGJ 2 . To overcome this problem we have used pyrrolidine dithiocarbamate and Tempol ( Fig.…”

Section: Dear Editormentioning

confidence: 99%

“…Using GC-MS/MS technology, Tsikas et al [1,13] determined 15d-PGJ 2 levels in urine of healthy donors in the pM range. It remains to be evaluated whether these findings can be extrapolated to 15d-PGJ 2 levels in serum/plasma or organs/tissues.…”

Section: Dear Editormentioning

confidence: 99%

“…It is currently not clear whether the urinary 15(S)-8-iso-PGF/15d-PGJ 2 ratio, as mentioned by Tsikas et al [1], might be considered a surrogate marker for the generation of 15d-PGJ 2 -mediated oxidative stress. However, a series of published articles revealed an association of 15d- …”

Section: Dear Editormentioning

confidence: 99%

See 2 more Smart Citations

Response to letter by Tsikas et al.

Koyani

Windischhofer

Rossmann

et al. 2014

International Journal of Cardiology

View full text Add to dashboard Cite

Sensitive mass spectrometric assay for determination of 15-deoxy-Δ12,14-prostaglandin J2 and its application in human plasma samples of patients with diabetes

et al. 2017

View full text Add to dashboard Cite

The determination of individual prostaglandins (PG) in humans is mainly performed in urine samples. The quantification of PGs in human plasma could improve the understanding of particular PG species under various physiological and pathological conditions. 15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is a dehydrated downstream product of PGD2 and is of high interest due to its recently discovered anti-inflammatory effects. Increasing availability of highly sensitive mass spectrometry allows the quantification of low abundant biomarkers like 15d-PGJ2 in human plasma samples. Herein, a sensitive LC-MS/MS method for the determination of 15d-PGJ2 was established. The method was validated according to the guidance of the American Food and Drug Administration and tested in plasma samples from patients with poorly controlled diabetes, considered to be a pro-inflammatory condition. Extraction of 15d-PGJ2 was achieved with an easy-to-use liquid-liquid extraction by ethyl acetate following a methanol precipitation. The lower limit of quantification was 2.5 pg mL−1 and linearity (R 2 = 0.998) was guaranteed between 2.5 and 500 pg mL−1 for 15d-PGJ2. Selectivity was assured by the use of two individual mass transitions (qualifier and quantifier). Precision and accuracy were validated in an inter- and intraday assay with a coefficient of variation below 11.8% (intraday) and 14.7% (interday). In diabetic patients with an HbA1C > 9%, increased plasma concentrations of 15d-PGJ2 compared to control plasma were measured. 15d-PGJ2 correlated negatively with the inflammation marker C-reactive protein. The developed LC-MS/MS method represents a new possibility to quantify 15d-PGJ2 with high specificity in human plasma samples. This may contribute to a better understanding of the potential anti-inflammatory effects of 15d-PGJ2 in severe long-term pro-inflammatory disorders like diabetes, cancer, or cardiovascular disease.Electronic supplementary materialThe online version of this article (10.1007/s00216-017-0748-1) contains supplementary material, which is available to authorized users.

show abstract

Response to letter by Tsikas et al. 15-deoxy-Δ12,14-PGJ2: An interesting but unapproachable pharmacological target?

Cited by 3 publications

References 17 publications

N-Acetylcysteine (NAC) inhibits renal nitrite and nitrate reabsorption in healthy subjects and in patients undergoing cardiac surgery: Risk of nitric oxide (NO) bioavailability loss by NAC?

N-Acetylcysteine (NAC) inhibits renal nitrite and nitrate reabsorption in healthy subjects and in patients undergoing cardiac surgery: Risk of nitric oxide (NO) bioavailability loss by NAC?

Response to letter by Tsikas et al.

Sensitive mass spectrometric assay for determination of 15-deoxy-Δ12,14-prostaglandin J2 and its application in human plasma samples of patients with diabetes

Contact Info

Product

Resources

About